# Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

> **NCT01084330** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 68 (actual)

## Conditions studied

- Advanced Gastric Cancer
- Gastro-esophageal Junction Cancer

## Interventions

- **DRUG:** AUY922
- **DRUG:** Docetaxel
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT01084330
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2020-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01084330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01084330, "Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01084330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*